A citation-based method for searching scientific literature

Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedinst. J Psychopharmacol 2016
Times Cited: 485







List of co-cited articles
854 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb,[...]. J Psychopharmacol 2016
411
63

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding,[...]. Lancet Psychiatry 2016
426
51

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
Michael P Bogenschutz, Alyssa A Forcehimes, Jessica A Pommy, Claire E Wilcox, P C R Barbosa, Rick J Strassman. J Psychopharmacol 2015
339
41

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer. Arch Gen Psychiatry 2011
404
39

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling,[...]. Psychopharmacology (Berl) 2018
210
37

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Alan K Davis, Frederick S Barrett, Darrick G May, Mary P Cosimano, Nathan D Sepeda, Matthew W Johnson, Patrick H Finan, Roland R Griffiths. JAMA Psychiatry 2021
128
35

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
Matthew W Johnson, Albert Garcia-Romeu, Mary P Cosimano, Roland R Griffiths. J Psychopharmacol 2014
293
34


Trial of Psilocybin versus Escitalopram for Depression.
Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts, Michelle Baker-Jones, Ashleigh Murphy-Beiner, Roberta Murphy, Jonny Martell, Allan Blemings, David Erritzoe, David J Nutt. N Engl J Med 2021
108
32

Psychedelics Promote Structural and Functional Neural Plasticity.
Calvin Ly, Alexandra C Greb, Lindsay P Cameron, Jonathan M Wong, Eden V Barragan, Paige C Wilson, Kyle F Burbach, Sina Soltanzadeh Zarandi, Alexander Sood, Michael R Paddy,[...]. Cell Rep 2018
222
30

Psychedelics.
David E Nichols. Pharmacol Rev 2016
417
28

Human hallucinogen research: guidelines for safety.
Mw Johnson, Wa Richards, Rr Griffiths. J Psychopharmacol 2008
299
28


Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
Roland R Griffiths, Matthew W Johnson, William A Richards, Brian D Richards, Una McCann, Robert Jesse. Psychopharmacology (Berl) 2011
287
27

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.
Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, Katia C Andrade, Morgana M Novaes, Jessica A Pessoa, Sergio A Mota-Rolim, Flávia L Osório, Rafael Sanches, Rafael G Dos Santos,[...]. Psychol Med 2019
184
25

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
Peter Gasser, Dominique Holstein, Yvonne Michel, Rick Doblin, Berra Yazar-Klosinski, Torsten Passie, Rudolf Brenneisen. J Nerv Ment Dis 2014
242
25

Long-term follow-up of psilocybin-facilitated smoking cessation.
Matthew W Johnson, Albert Garcia-Romeu, Roland R Griffiths. Am J Drug Alcohol Abuse 2017
148
25

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
Albert Garcia-Romeu, Roland R Griffiths, Matthew W Johnson. Curr Drug Abuse Rev 2014
153
24

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
Francisco A Moreno, Christopher B Wiegand, E Keolani Taitano, Pedro L Delgado. J Clin Psychiatry 2006
229
23

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
F X Vollenweider, M F Vollenweider-Scherpenhuyzen, A Bäbler, H Vogel, D Hell. Neuroreport 1998
470
22

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.
Robin L Carhart-Harris, David Erritzoe, Tim Williams, James M Stone, Laurence J Reed, Alessandro Colasanti, Robin J Tyacke, Robert Leech, Andrea L Malizia, Kevin Murphy,[...]. Proc Natl Acad Sci U S A 2012
372
20

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
Frederick S Barrett, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2015
124
19

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.
Gabrielle I Agin-Liebes, Tara Malone, Matthew M Yalch, Sarah E Mennenga, K Linnae Ponté, Jeffrey Guss, Anthony P Bossis, Jim Grigsby, Stacy Fischer, Stephen Ross. J Psychopharmacol 2020
63
30

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
Erich Studerus, Michael Kometer, Felix Hasler, Franz X Vollenweider. J Psychopharmacol 2011
180
18

Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
Martin K Madsen, Patrick M Fisher, Daniel Burmester, Agnete Dyssegaard, Dea S Stenbæk, Sara Kristiansen, Sys S Johansen, Sczabolz Lehel, Kristian Linnet, Claus Svarer,[...]. Neuropsychopharmacology 2019
83
21



Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
Katherine A MacLean, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2011
260
16

The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation.
Katrin H Preller, Marcus Herdener, Thomas Pokorny, Amanda Planzer, Rainer Kraehenmann, Philipp Stämpfli, Matthias E Liechti, Erich Seifritz, Franz X Vollenweider. Curr Biol 2017
149
15

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
Matthew W Johnson, Roland R Griffiths, Peter S Hendricks, Jack E Henningfield. Neuropharmacology 2018
79
18


Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
Roland R Griffiths, Matthew W Johnson, William A Richards, Brian D Richards, Robert Jesse, Katherine A MacLean, Frederick S Barrett, Mary P Cosimano, Maggie A Klinedinst. J Psychopharmacol 2018
100
15

Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.
Brian T Anderson, Alicia Danforth, Prof Robert Daroff, Christopher Stauffer, Eve Ekman, Gabrielle Agin-Liebes, Alexander Trope, Matthew Tyler Boden, Prof James Dilley, Jennifer Mitchell,[...]. EClinicalMedicine 2020
39
38

Cessation and reduction in alcohol consumption and misuse after psychedelic use.
Albert Garcia-Romeu, Alan K Davis, Fire Erowid, Earth Erowid, Roland R Griffiths, Matthew W Johnson. J Psychopharmacol 2019
51
27

Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.
Felix Hasler, Ulrike Grimberg, Marco A Benz, Theo Huber, Franz X Vollenweider. Psychopharmacology (Berl) 2004
163
14


Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.
Tehseen Noorani, Albert Garcia-Romeu, Thomas C Swift, Roland R Griffiths, Matthew W Johnson. J Psychopharmacol 2018
47
29


The pharmacology of psilocybin.
Torsten Passie, Juergen Seifert, Udo Schneider, Hinderk M Emrich. Addict Biol 2002
142
13

Psychedelics and the essential importance of context.
Robin L Carhart-Harris, Leor Roseman, Eline Haijen, David Erritzoe, Rosalind Watts, Igor Branchi, Mendel Kaelen. J Psychopharmacol 2018
120
13

Psychedelics and Psychedelic-Assisted Psychotherapy.
Collin M Reiff, Elon E Richman, Charles B Nemeroff, Linda L Carpenter, Alik S Widge, Carolyn I Rodriguez, Ned H Kalin, William M McDonald. Am J Psychiatry 2020
84
15

Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.
Friederike Holze, Patrick Vizeli, Laura Ley, Felix Müller, Patrick Dolder, Melanie Stocker, Urs Duthaler, Nimmy Varghese, Anne Eckert, Stefan Borgwardt,[...]. Neuropsychopharmacology 2021
43
30

Neural correlates of the LSD experience revealed by multimodal neuroimaging.
Robin L Carhart-Harris, Suresh Muthukumaraswamy, Leor Roseman, Mendel Kaelen, Wouter Droog, Kevin Murphy, Enzo Tagliazucchi, Eduardo E Schenberg, Timothy Nest, Csaba Orban,[...]. Proc Natl Acad Sci U S A 2016
265
12

Psychedelics as Medicines: An Emerging New Paradigm.
D E Nichols, M W Johnson, C D Nichols. Clin Pharmacol Ther 2017
100
12

The Current Status of Psychedelics in Psychiatry.
David Nutt, Robin Carhart-Harris. JAMA Psychiatry 2021
32
37

Effects of psilocybin therapy on personality structure.
D Erritzoe, L Roseman, M M Nour, K MacLean, M Kaelen, D J Nutt, R L Carhart-Harris. Acta Psychiatr Scand 2018
65
18

Emotions and brain function are altered up to one month after a single high dose of psilocybin.
Frederick S Barrett, Manoj K Doss, Nathan D Sepeda, James J Pekar, Roland R Griffiths. Sci Rep 2020
53
22

Psychedelic Psychiatry's Brave New World.
David Nutt, David Erritzoe, Robin Carhart-Harris. Cell 2020
63
19

Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.
Javier González-Maeso, Noelia V Weisstaub, Mingming Zhou, Pokman Chan, Lidija Ivic, Rosalind Ang, Alena Lira, Maria Bradley-Moore, Yongchao Ge, Qiang Zhou,[...]. Neuron 2007
452
12

Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.
Yasmin Schmid, Florian Enzler, Peter Gasser, Eric Grouzmann, Katrin H Preller, Franz X Vollenweider, Rudolf Brenneisen, Felix Müller, Stefan Borgwardt, Matthias E Liechti. Biol Psychiatry 2015
186
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.